Clinical trial / 2008
A 3.0 g/day dose of maca root significantly improved SSRI-induced sexual dysfunction scores, whereas a 1.5 g/day dose did not.
A double-blind pilot study evaluated low-dose (1.5 g/day) versus high-dose (3.0 g/day) maca in 20 remitted depressed outpatients with SSRI-induced sexual dysfunction. In intent-to-treat analyses, subjects on 3.0 g/day showed significant improvements in ASEX scores (from 22.8 +/- 3.8 to 16.9 +/- 6.2; P=0.028) and MGH-SFQ scores (from 24.1 +/- 1.9 to 17.0 +/- 5.7; P=0.017), while those on 1.5 g/day did not. Libido improved significantly based on ASEX item #1 for the ITT and completer groups (P<0.05), but not when analyzed by dosing groups. Maca was well tolerated.
- Study type
- Double-blind, randomized, parallel-group pilot dose-finding trial
- Who was studied
- 20 remitted depressed outpatients (mean age 36 +/- 13 years; 17 women) with SSRI-induced sexual dysfunction
- What was measured
- Sexual dysfunction measured by ASEX and MGH-SFQ scores, and libido
THE PAPER
A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.
Dording CM, Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. CNS Neurosci Ther, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.